FILANA THERAPEUTICS, INC. Material Event - Investor Briefing

Filana Therapeutics (formerly Cassava Sciences, NASDAQ: FLNA) delivered a shockwave to investors with its latest SEC filing. This briefing breaks down the significant developments in plain language, focusing on what matters most for you.

1. What Happened? Filana Therapeutics filed an 8-K with the SEC on March 12, 2026, before market open, announcing its full-year 2025 financial results and a dramatic strategic overhaul.

Here are the critical takeaways:

• Complete Strategic Shift: Filana has officially abandoned its entire Alzheimer's disease drug program, marking a definitive end to its former primary focus.
• New Lead Drug on Clinical Hold: Its new lead drug, simufilam for TSC-related epilepsy (a rare genetic disorder), is now under a "clinical hold" by the FDA (U.S. Food and Drug Administration). Issued in December 2025, this regulatory action has paused all clinical trials for simufilam as the FDA reviews additional data and proposed study modifications from Filana.
• Worsening Financials: Filana reported a substantial net loss of $91.0 million for 2025, a sharp increase from $24.3 million in 2024. The company's operations consumed $32.3 million in cash during 2025 and project significantly higher cash burn in the first half of 2026.
• Major Legal Settlement: Filana must pay $31.25 million to settle past securities litigation, further straining its finances. The announcement did not specify the exact due date for this payment.

2. When Did It Happen? Filana officially announced these events on March 12, 2026. The FDA placed simufilam on clinical hold in December 2025, following the gradual phasing out of the Alzheimer's program between late 2024 and mid-2025.

3. Why Did It Happen? Filana initiated a complete strategic pivot, primarily driven by the high costs and extensive resource demands of its former Alzheimer's program. By discontinuing this program, the company aims to conserve capital and concentrate entirely on simufilam for TSC-related epilepsy.

The simufilam clinical hold signals that the FDA has concerns or requires more data before allowing trials to proceed. While not a definitive rejection, it represents a serious regulatory roadblock. Filana is now working to address these concerns by providing additional pre-clinical data and revising its study plans, aiming to lift the hold.

Financially, the company's escalating net losses and cash burn underscore the inherent high costs of drug development, further compounded by the significant legal settlement. This severe financial strain largely drove their strategic re-evaluation.

4. Why Does This Matter? This 8-K filing signals a profound strategic shift and introduces substantial risks for Filana Therapeutics:

• High-Stakes Bet: Filana has abandoned its previous flagship program, making it entirely reliant on simufilam, a single new lead drug currently stalled by regulators. This represents an extremely high-risk strategy.
• Regulatory Uncertainty: The clinical hold generates immense uncertainty about simufilam's future. There is no guarantee the FDA will lift the hold, nor is the duration of the review process clear, potentially delaying revenue for years.
• Severe Financial Strain: With a net loss of $91.0 million in 2025 and $32.3 million in cash consumed by operations, Filana is rapidly depleting its resources. The additional $31.25 million litigation payment will further strain its liquidity. Without clear projections for cash on hand or a detailed cash runway, investors face significant uncertainty regarding the company's ability to fund operations and clinical development. This situation likely necessitates raising substantial new capital, which could dilute existing shares.

5. Who Is Affected?

• Patients: These program changes and delays directly impact patients with Alzheimer's disease who followed Filana's previous work, as well as those with TSC-related epilepsy awaiting new treatments.
• Filana Employees: Employees, especially those involved in the Alzheimer's program, have faced or will face job uncertainty. The clinical hold also creates uncertainty for those working on simufilam.
• Investors/Shareholders: Owners of Filana stock (FLNA) will likely experience significant volatility and potential declines in their investment. This stems from increased financial losses, ongoing cash burn, and critical uncertainty surrounding the company's sole clinical-stage program.
• The Company Itself: Filana faces a challenging path. It must successfully navigate FDA requirements, manage rapidly diminishing cash reserves, and prove the viability of its new strategic direction.

6. What Happens Next? Investors should expect Filana's stock price to be highly volatile, likely trending downwards, as the market processes this news. The company's immediate priority is to comprehensively respond to the FDA's requests to lift the simufilam clinical hold. This process can be lengthy, potentially taking months, with no assurance of a positive outcome. Filana must also meticulously manage its remaining cash, especially with the substantial litigation payment pending. The company has stated a focus on "capital efficiency" to extend its financial runway.

7. What Should Investors/Traders Know? If you hold Filana stock, prepare for a potentially sharp and sustained decline in value. The company has completely abandoned its prior focus, and its new lead drug faces a regulatory hold, creating a highly uncertain future. Significant financial losses, ongoing cash burn, and a substantial legal payment severely pressure the company's cash reserves, raising serious questions about its long-term viability without securing additional funding.

For prospective investors, Filana Therapeutics now presents an extremely high-risk profile. The inherent risks of drug development are amplified by a complete strategic pivot, a regulatory hold on its sole clinical asset, and significant financial challenges. It is crucial to re-evaluate this investment against your personal risk tolerance and financial goals.